Neutron capture therapy for melanoma
The development of boron-containing compounds which localize selectively in tumor may require a tumor-by-tumor type of approach that exploits any metabolic pathways unique to the particular type of tumor. Melanin-producing melanomas actively transport and metabolize aromatic amino acids for use as precursors in the synthesis of the pigment melanin. It has been shown that the boron-containing amino acid analog p-borono-phenylalanine (BPA) is selectively accumulated in melanoma tissue, producing boron concentrations in tumor that are within the range estimated to be necessary for successful boron neutron capture therapy (BNCT). We report here the results of therapy experiments carried out at the Brookhaven Medical Research Reactor (BMRR). 21 refs., 5 figs., 3 tabs.
- Research Organization:
- Brookhaven National Lab., Upton, NY (USA)
- Sponsoring Organization:
- DOE/ER
- DOE Contract Number:
- AC02-76CH00016
- OSTI ID:
- 5468867
- Report Number(s):
- BNL-43086; CONF-8802102--6; ON: DE90001331
- Country of Publication:
- United States
- Language:
- English
Similar Records
Experimental boron neutron capture therapy for melanoma: Systemic delivery of boron to melanotic and amelanotic melanoma
Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine